 | Up a level |
Limmroth, V., Haverkamp, W., Dechend, R., Kleiter, I., Wagner, B., Schmidt, S., Lassek, C., Wendt, G. and Ziemssen, T. (2017). First dose effects of fingolimod: final results of an in-depth ECG and Holter study in 6,998 German RRMS patients. Mult. Scler. J., 23. S. 383 - 385. LONDON: SAGE PUBLICATIONS LTD. ISSN 1477-0970
Limmroth, V., Haverkamp, W., Dechend, R., Lang, M., Haas, J., Wagner, B., Richter, S., Schieb, H., Wendt, G. and Ziemssen, T. (2016). First dose effects of fingolimod: in depth electrocardiographic analysis of over 4.700 patients confirms first dose observation is usually uneventful. Mult. Scler. J., 22. S. 356 - 357. LONDON: SAGE PUBLICATIONS LTD. ISSN 1477-0970
Schlieper, G., Remppis, A., Schwenger, V., Keller, T., Dechend, R., Massberg, S., Baldus, S., Weinreich, T., Hetzel, G., Floege, J., Hoyer, J., Mahfoud, F. and Fliser, D. (2018). Non-vitamin K antagonist oral anticoagulants (NOAC) in chronic kidney disease. Recommendations of the working group Heart-Kidneys, of the German Cardiac Society and the German Society of Nephrology. Nephrologe, 13 (2). S. 91 - 99. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1862-0418
Schlieper, G., Schwenger, V., Remppis, A., Keller, T., Dechend, R., Massberg, S., Baldus, S., Weinreich, T., Hetzel, G., Floege, J., Mahfoud, F. and Fliser, D. (2017). Anticoagulation in patients with chronic kidney disease Recommendations from the working group Heart-Kidney of the German Cardiac Society and the German Society of Nephrology. Internist, 58 (5). S. 512 - 522. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1289